|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
|
US5278056A
(en)
|
1988-02-05 |
1994-01-11 |
The Trustees Of Columbia University In The City Of New York |
Retroviral packaging cell lines and process of using same
|
|
US5670488A
(en)
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
|
AU8200191A
(en)
|
1990-07-09 |
1992-02-04 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
High efficiency packaging of mutant adeno-associated virus using amber suppressions
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
ATE237694T1
(de)
|
1991-08-20 |
2003-05-15 |
Us Gov Health & Human Serv |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
JP3866760B2
(ja)
|
1993-02-22 |
2007-01-10 |
ザ ロックフェラー ユニバーシティ |
一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
|
|
FR2712812B1
(fr)
|
1993-11-23 |
1996-02-09 |
Centre Nat Rech Scient |
Composition pour la production de produits thérapeutiques in vivo.
|
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
CA2554380C
(en)
*
|
2004-02-17 |
2015-05-19 |
The Hospital For Sick Children |
Mecp2e1 gene
|
|
ES2582200T3
(es)
*
|
2007-09-12 |
2016-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Utilización de vectores víricos portadores del gen CYP46A1 para el tratamiento de la enfermedad de Alzheimer
|
|
ES2566495T3
(es)
*
|
2010-10-15 |
2016-04-13 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Vector de expresión para colesterol 24-hidrolasa en terapia de la enfermedad de Huntington
|
|
SG10201707569YA
(en)
*
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
KR20250012194A
(ko)
*
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
EP3013371A4
(en)
*
|
2013-06-26 |
2017-04-26 |
Rett Syndrome Research Trust |
Rett syndrome and treatments therefore
|
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
RU2017110868A
(ru)
*
|
2014-09-25 |
2018-10-25 |
Колд Спринг Харбор Лаборатори |
Лечение синдрома ретта
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
FI3574091T3
(fi)
*
|
2017-01-30 |
2023-05-03 |
Brainvectis |
Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa
|
|
EP3388520A1
(en)
*
|
2017-04-11 |
2018-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
|
|
EP3635122A4
(en)
*
|
2017-06-06 |
2021-03-31 |
University of Massachusetts |
SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME
|